CSIMarket
 
Athenex Inc   (ATNX)
Other Ticker:  
 
 
Price: $0.2031 $-0.06 -23.387%
Day's High: $0.2571 Week Perf: -46.55 %
Day's Low: $ 0.20 30 Day Perf: -82.49 %
Volume (M): 1,880 52 Wk High: $ 1.66
Volume (M$): $ 382 52 Wk Avg: $1.11
Open: $0.22 52 Wk Low: $0.20



 Market Capitalization (Millions $) 23
 Shares Outstanding (Millions) 113
 Employees 1,115
 Revenues (TTM) (Millions $) 103
 Net Income (TTM) (Millions $) -104
 Cash Flow (TTM) (Millions $) -54
 Capital Exp. (TTM) (Millions $) 0

Athenex Inc
Athenex Inc. is an innovative pharmaceutical company that specializes in the development and commercialization of novel therapies for the treatment of cancer and other diseases. The company was founded in 2003 and primarily operates in the United States.

Athenex Inc. operates through three main segments: Oncology Innovation Platform, Commercial Platform, and Global Supply Chain Platform. The Oncology Innovation Platform focuses on the research and development of new drugs for the treatment of cancer. The Commercial Platform is responsible for marketing and sales of the products developed by the Oncology Innovation Platform, and the Global Supply Chain Platform oversees the manufacturing and distribution of these products.

The company has a broad pipeline of products in development, with a focus on oncology, including breast cancer, liver cancer, and bladder cancer. Athens has several proprietary drug delivery technologies, such as Orasolv and QrxPharmaceutics that improve the solubility and bioavailability of poorly soluble drugs.

Athenex Inc. has a strong commitment to international development, with a focus on emerging markets, particularly in Asia. The company has partnered with several leading pharmaceutical companies in China to develop and commercialize its cancer drugs.

Additionally, Athenex Inc. is also leading the race to develop a COVID-19 vaccine as the company has partnered with Bharat Biotech in India, the largest vaccine manufacturer, and the University of Hong Kong.

In summary, Athenex Inc. is a global pharmaceutical company that focuses on oncology treatments and drug delivery technologies. It has a strong commitment to emerging markets, particularly in Asia, and has a broad pipeline of products in development for the treatment of cancer and other diseases. The company is also leading the race to develop a COVID-19 vaccine.


   Company Address: 1001 Main Street Buffalo 14203 NY
   Company Phone Number: 427-2950   Stock Exchange / Ticker: NASDAQ ATNX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Stock Plunge and Financial Contraction in Fiscal Fourth Quarter of 2023

Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average.
The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.

Soligenix Inc

Soligenix Inc Narrows Fourth Quarter Shortfall 2.

As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year.
In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance.
Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.

Eterna Therapeutics Inc

Eterna Therapeutics Inc Reports Revenue of $0.017 Million in Q4 2023 Financial Results

In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products.
Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.






 

Athenex Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com